Singapore: +65-85097465 | India: +91-40-42023318
  U.S / Canada Toll Free: +1-866-259-4781
  Zimbabwe: +263-735539685, 773876488

          

Clinical Trial News

Experimental drug 'successfully treated doctor who contracted Ebola'

A drug currently being tested against vascular leakage successfully treated a doctor who contracted Ebola in Sierra Leone, according to a new report published in The Lancet.

New hope for rare disease drug development - Charcot-Marie-Tooth type 1A disease (CMT1A)

Using combinations of well-known approved drugs has for the first time been shown to be potentially safe in treating a rare disease, according to the results of a clinical trial published in the...

53 Ebola-blocking drugs identified among existing medications

Using high-speed screening technology, researchers have identified 53 drugs - including some antihistamines and antidepressants - that may prevent Ebola from entering human cells.

Herceptin for HER2-positive breast cancer improves long-term survival

A new study shows that when added to chemotherapy, trastuzumab - commonly known as Herceptin - significantly improves long-term survival of HER2-positive breast cancer patients.

VR475 shown significant benefit in a Phase IIb/III trial for severe asthma

Vectura Group plc has announced the publication in the European Respiratory Journal (ERJ) of a clinical study demonstrating positive results from its Phase IIb/III (Acti-AICS-001) clinical trial...

Tamoxifen has reduced breast cancer rates 'by a third'

A well-established and effective treatment for breast cancer, tamoxifen has now been shown to have long-term preventive benefits for women at high risk.

Primary data from Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy announced

UCB has announced the primary efficacy and safety data from the latest Phase 3 study evaluating brivaracetam (fixed doses of 100 and 200 mg/day with no up-titration) as adjunctive treatment in...

Follow-up data from idelalisib (Zydelig) registrational studies in patients with chronic lymphocytic leukaemia and follicular lympho

Gilead Sciences, Inc. has announced long-term follow-up results from the registration studies further describing the duration of response, progression-free survival (PFS) and the safety profile for...



James Lind Institute Newsletter
James Lind Institute Linkedin
James Lind Institute RSS
James Lind Institute Email Update
James Lind Institute Blog
James Lind Institute Facebook